Literature DB >> 15477647

Construction and characterization of a minimized version of the HIV-1 pNL4-3 plasmid and its application for pseudotyping HIV-1 vectors.

María Luisa Abad1, Tomás Verdura, Alicia Vela, María José Iglesias, Dolores Gutiérrez, Manuel Veiga, Antonio Aguilera, Benito J Regueiro.   

Abstract

The pUC-based pNL4-3 plasmid is the most widely used vector for in vitro manipulations of the HIV-1 proviral sequences. We have developed a minimal plasmid (pCHUS) based on pNL4-3, which may be useful to facilitate the design of HIV-based constructions. The strategy that has allowed us to construct pCHUS includes the following steps: (1) pNL4-3 digestion by using restriction sites contained within the long terminal repeats (LTRs), (2) recircularization of the fragment containing the pUC18 sequence, (3) amplification of the LTR region restored in the previous step, (4) double digestion of the products obtained in steps 2 and 3, (5) ligation of the fragment containing ColE1+Amp(R) with the LTR fragment, (6) linearization of the intermediate plasmid obtained, and (7) insertion of the fragment containing the proviral genome into the linearized vector. The pCHUS plasmid includes essential information for its replication and antibiotic selection in bacteria, but it lacks all the unnecessary sequences. Our results suggest that pCHUS may be more advantageous than pNL4-3 for in vitro manipulation of the HIV-1 proviral genome. In addition, we describe a potential application of this new vector for pseudotyping HIV-1 particles, using a single plasmid transfection, as a more helpful alternative to the traditionally used cotransfection method.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15477647     DOI: 10.1385/MB:28:2:087

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  7 in total

1.  Intervening sequences increase efficiency of RNA 3' processing and accumulation of cytoplasmic RNA.

Authors:  M T Huang; C M Gorman
Journal:  Nucleic Acids Res       Date:  1990-02-25       Impact factor: 16.971

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  Reduction in growth temperature minimizes instability of large plasmids containing HIV-1 proviral genomes.

Authors:  A Joshi; K T Jeang
Journal:  Biotechniques       Date:  1993-06       Impact factor: 1.993

4.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.

Authors:  R B DuBridge; P Tang; H C Hsia; P M Leong; J H Miller; M P Calos
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

5.  Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein.

Authors:  S R Bartz; M A Vodicka
Journal:  Methods       Date:  1997-08       Impact factor: 3.608

6.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  A new reporter cell line to monitor HIV infection and drug susceptibility in vitro.

Authors:  A Gervaix; D West; L M Leoni; D D Richman; F Wong-Staal; J Corbeil
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

  7 in total
  1 in total

Review 1.  HIV-1 and drug abuse comorbidity: Lessons learned from the animal models of NeuroHIV.

Authors:  Susmita Sil; Annadurai Thangaraj; Ernest T Chivero; Fang Niu; Muthukumar Kannan; Ke Liao; Peter S Silverstein; Palsamy Periyasamy; Shilpa Buch
Journal:  Neurosci Lett       Date:  2021-03-29       Impact factor: 3.197

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.